![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: FBXL18 |
Gene summary for FBXL18 |
![]() |
Gene information | Species | Human | Gene symbol | FBXL18 | Gene ID | 80028 |
Gene name | F-box and leucine rich repeat protein 18 | |
Gene Alias | Fbl18 | |
Cytomap | 7p22.1 | |
Gene Type | protein-coding | GO ID | GO:0006508 | UniProtAcc | B4DH63 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
80028 | FBXL18 | HCC1_Meng | Human | Liver | HCC | 2.10e-05 | -5.92e-02 | 0.0246 |
80028 | FBXL18 | HCC1 | Human | Liver | HCC | 1.10e-18 | 2.91e+00 | 0.5336 |
80028 | FBXL18 | HCC2 | Human | Liver | HCC | 4.39e-33 | 3.19e+00 | 0.5341 |
80028 | FBXL18 | HCC5 | Human | Liver | HCC | 3.18e-32 | 2.25e+00 | 0.4932 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Endometrium | ![]() | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer | ||
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001049822 | Liver | HCC | proteasomal protein catabolic process | 351/7958 | 490/18723 | 6.92e-40 | 1.46e-36 | 351 |
GO:004316122 | Liver | HCC | proteasome-mediated ubiquitin-dependent protein catabolic process | 299/7958 | 412/18723 | 7.82e-36 | 8.27e-33 | 299 |
GO:0031146 | Liver | HCC | SCF-dependent proteasomal ubiquitin-dependent protein catabolic process | 30/7958 | 49/18723 | 6.31e-03 | 2.57e-02 | 30 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FBXL18 | SNV | Missense_Mutation | c.1082C>T | p.Ser361Leu | p.S361L | Q96ME1 | protein_coding | tolerated(0.16) | benign(0.003) | TCGA-AN-A0FL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
FBXL18 | SNV | Missense_Mutation | c.623N>A | p.Arg208His | p.R208H | Q96ME1 | protein_coding | tolerated(0.06) | probably_damaging(0.966) | TCGA-BH-A1EN-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
FBXL18 | SNV | Missense_Mutation | c.232T>G | p.Tyr78Asp | p.Y78D | Q96ME1 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-E2-A1IE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD | |
FBXL18 | deletion | In_Frame_Del | novel | c.2145_2150delNNNNNN | p.Asn715_Trp717delinsLys | p.N715_W717delinsK | Q96ME1 | protein_coding | TCGA-OL-A66P-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | CR | ||
FBXL18 | SNV | Missense_Mutation | novel | c.304G>A | p.Ala102Thr | p.A102T | Q96ME1 | protein_coding | tolerated(1) | benign(0.436) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
FBXL18 | SNV | Missense_Mutation | c.922C>A | p.Leu308Met | p.L308M | Q96ME1 | protein_coding | tolerated(0.09) | probably_damaging(0.935) | TCGA-EK-A2RB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
FBXL18 | SNV | Missense_Mutation | c.641C>T | p.Ser214Leu | p.S214L | Q96ME1 | protein_coding | deleterious(0.01) | possibly_damaging(0.806) | TCGA-EK-A2RN-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
FBXL18 | SNV | Missense_Mutation | c.625N>A | p.Glu209Lys | p.E209K | Q96ME1 | protein_coding | deleterious(0.01) | probably_damaging(0.997) | TCGA-VS-A959-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
FBXL18 | SNV | Missense_Mutation | rs766143098 | c.1637N>T | p.Thr546Met | p.T546M | Q96ME1 | protein_coding | tolerated(0.21) | possibly_damaging(0.804) | TCGA-A6-2672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
FBXL18 | SNV | Missense_Mutation | novel | c.35N>G | p.Asp12Gly | p.D12G | Q96ME1 | protein_coding | tolerated_low_confidence(0.32) | benign(0) | TCGA-A6-2672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |